50-199-3619
KDM4C Polyclonal Antibody, Active Motif™
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-199-3619-Each-of-1 | In Stock | ₹ 12,834.00 |
50-199-3619 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 12,834.00
GST (18%): ₹ 2,310.12
Total Price: ₹ 15,144.12
Antigen
KDM4C
Classification
Polyclonal
Conjugate
Unconjugated
Gene Alias
2410141F18Rik; AA517467; bA146B14.1; GASC1; GASC-1 protein; gene amplified in squamous cell carcinoma 1; Gene amplified in squamous cell carcinoma 1 protein; JHDM3C; JmjC domain-containing histone demethylation protein 3C; Jmjd2c; jumonji domain containing 2C; Jumonji domain-containing protein 2C; KDM4C; KIAA0780; lysine (K)-specific demethylase 4C; lysine demethylase 4C; Lysine-specific demethylase 4C; RP11-169L18.1; TDRD14C; tudor domain containing 14C
Immunogen
This antibody was raised against a peptide within human kDM4C.
Quantity
10 μL
Primary or Secondary
Primary
Content And Storage
-20°C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
Western Blot
Concentration
Lot-Specific
Formulation
PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Target Species
Monkey
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Jumonji domain-containing protein 2C (JMJD2C)/ Lysine-specific demethylase 4C (KDM4C) is a histone demethylase that specifically demethylates 'Lys-9' and 'Lys-36' residues of histone H3; thereby, playing a central role in histone code
- KDM4C does not demethylate histone H3 'Lys-4', H3 'Lys-27', or H4 'Lys-20'
- It demethylates trimethylated H3 'Lys-9' and H3 'Lys-36' residues
- There is no activity on mono- or dimethylated residues
- Demethylation of Lys residues generates formaldehyde and succinate.
Compare Similar Items
Show Difference
Antigen: KDM4C
Classification: Polyclonal
Conjugate: Unconjugated
Gene Alias: 2410141F18Rik; AA517467; bA146B14.1; GASC1; GASC-1 protein; gene amplified in squamous cell carcinoma 1; Gene amplified in squamous cell carcinoma 1 protein; JHDM3C; JmjC domain-containing histone demethylation protein 3C; Jmjd2c; jumonji domain containing 2C; Jumonji domain-containing protein 2C; KDM4C; KIAA0780; lysine (K)-specific demethylase 4C; lysine demethylase 4C; Lysine-specific demethylase 4C; RP11-169L18.1; TDRD14C; tudor domain containing 14C
Immunogen: This antibody was raised against a peptide within human kDM4C.
Quantity: 10 μL
Primary or Secondary: Primary
Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: Western Blot
Concentration: Lot-Specific
Formulation: PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species: Rabbit
Purification Method: Antigen affinity chromatography
Regulatory Status: RUO
Target Species: Monkey
Product Type: Antibody
Isotype: IgG
Antigen:
KDM4C
Classification:
Polyclonal
Conjugate:
Unconjugated
Gene Alias:
2410141F18Rik; AA517467; bA146B14.1; GASC1; GASC-1 protein; gene amplified in squamous cell carcinoma 1; Gene amplified in squamous cell carcinoma 1 protein; JHDM3C; JmjC domain-containing histone demethylation protein 3C; Jmjd2c; jumonji domain containing 2C; Jumonji domain-containing protein 2C; KDM4C; KIAA0780; lysine (K)-specific demethylase 4C; lysine demethylase 4C; Lysine-specific demethylase 4C; RP11-169L18.1; TDRD14C; tudor domain containing 14C
Immunogen:
This antibody was raised against a peptide within human kDM4C.
Quantity:
10 μL
Primary or Secondary:
Primary
Content And Storage:
-20°C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
Western Blot
Concentration:
Lot-Specific
Formulation:
PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species:
Rabbit
Purification Method:
Antigen affinity chromatography
Regulatory Status:
RUO
Target Species:
Monkey
Product Type:
Antibody
Isotype:
IgG
Antigen: CDKN2A p14ARF
Classification: Polyclonal
Conjugate: Unconjugated
Gene Alias: Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; p14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16ink4a; p16-INK4a; P19; P19 TP16; p19; p19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: This antibody was raised against a peptide within the N-terminal region of human CDkN2A p14ARF.
Quantity: 100 μL
Primary or Secondary: Primary
Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: Western Blot
Concentration: Lot-Specific
Formulation: PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species: Rabbit
Purification Method: Antigen affinity chromatography
Regulatory Status: RUO
Target Species: Human
Product Type: Antibody
Isotype: IgG
Antigen:
CDKN2A p14ARF
Classification:
Polyclonal
Conjugate:
Unconjugated
Gene Alias:
Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; p14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16ink4a; p16-INK4a; P19; P19 TP16; p19; p19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
This antibody was raised against a peptide within the N-terminal region of human CDkN2A p14ARF.
Quantity:
100 μL
Primary or Secondary:
Primary
Content And Storage:
-20°C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
Western Blot
Concentration:
Lot-Specific
Formulation:
PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species:
Rabbit
Purification Method:
Antigen affinity chromatography
Regulatory Status:
RUO
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG
Antigen: CDKN2A p14ARF
Classification: Polyclonal
Conjugate: Unconjugated
Gene Alias: Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; p14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16ink4a; p16-INK4a; P19; P19 TP16; p19; p19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: This antibody was raised against a peptide within the N-terminal region of human CDkN2A p14ARF.
Quantity: 10 μL
Primary or Secondary: Primary
Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: Western Blot
Concentration: Lot-Specific
Formulation: PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species: Rabbit
Purification Method: Antigen affinity chromatography
Regulatory Status: RUO
Target Species: Human
Product Type: Antibody
Isotype: IgG
Antigen:
CDKN2A p14ARF
Classification:
Polyclonal
Conjugate:
Unconjugated
Gene Alias:
Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; p14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16ink4a; p16-INK4a; P19; P19 TP16; p19; p19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
This antibody was raised against a peptide within the N-terminal region of human CDkN2A p14ARF.
Quantity:
10 μL
Primary or Secondary:
Primary
Content And Storage:
-20°C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
Western Blot
Concentration:
Lot-Specific
Formulation:
PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species:
Rabbit
Purification Method:
Antigen affinity chromatography
Regulatory Status:
RUO
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG
Antigen: ACTL6B
Classification: Polyclonal
Conjugate: Unconjugated
Gene Alias: 53 kDa BRG1-associated factor B; actin like 6B; actin-like 6; actin-like 6B; Actin-like protein 6B; actin-like protein 6B {ECO:0000250; Actin-related protein Baf53b; Actl6; ACTL6B; actl6b {ECO:0000250; Arpna; ArpNalpha; ArpN-alpha; BAF53B; BRG1-associated factor 53B; hArpN alpha; UniProtKB:O94805}
Immunogen: This antibody was raised against a peptide within the N-terminal region of human ACTL6B.
Quantity: 100 μL
Primary or Secondary: Primary
Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
Form: Liquid
Applications: Western Blot
Concentration: Lot-Specific
Formulation: PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species: Rabbit
Purification Method: Antigen affinity chromatography
Regulatory Status: RUO
Target Species: Human
Product Type: Antibody
Isotype: IgG
Antigen:
ACTL6B
Classification:
Polyclonal
Conjugate:
Unconjugated
Gene Alias:
53 kDa BRG1-associated factor B; actin like 6B; actin-like 6; actin-like 6B; Actin-like protein 6B; actin-like protein 6B {ECO:0000250; Actin-related protein Baf53b; Actl6; ACTL6B; actl6b {ECO:0000250; Arpna; ArpNalpha; ArpN-alpha; BAF53B; BRG1-associated factor 53B; hArpN alpha; UniProtKB:O94805}
Immunogen:
This antibody was raised against a peptide within the N-terminal region of human ACTL6B.
Quantity:
100 μL
Primary or Secondary:
Primary
Content And Storage:
-20°C, Avoid Freeze/Thaw Cycles
Form:
Liquid
Applications:
Western Blot
Concentration:
Lot-Specific
Formulation:
PBS with 30% glycerol and 0.035% sodium azide; pH 7.5
Host Species:
Rabbit
Purification Method:
Antigen affinity chromatography
Regulatory Status:
RUO
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG